Throughout 2026, we’re celebrating the many “firsts” that have made CHOP a world leader in pediatric healthcare. Today’s highlight: the first FDA-approved gene therapy for an inherited condition. Developed at CHOP and pennmedicine, LUXTURNA provided hope for children with a rare form of congenital blindness. When Hannah received it at age 7, it restored her vision — a breakthrough made possible by decades of research, collaboration and innovation. Learn more about Hannah at the link in our bio. #PhillyFirst #Philly2026